|
2,002
|
| 15885 |
Angiotensin (1-7)
|
|
decreases_activity of
|
smooth muscle cell proliferation
|
in vascular smooth muscle; if induced by angiotensin II, via MAS1
|
| 15886 |
Angiotensin (1-7)
|
|
decreases_activity of
|
Angiotensin II
|
in vascular smooth muscle
|
| 15890 |
A-779
|
|
decreases_activity of
|
Angiotensin (1-7)
|
|
| 15893 |
Angiotensin (1-7)
|
NOT |
increases_activity of
|
smooth muscle cell migration
|
in vascular smooth muscle
|
| 15894 |
Angiotensin (1-7)
|
|
affects_activity of
|
smooth muscle cell migration
|
in vascular smooth muscle; via inhibition of angiotensin II
|
| 15898 |
Angiotensin (1-7)
|
|
affects_phosphorylation of
|
MAPK3/1
|
in vascular smooth muscle; via inhibition of angiotensin II
|
|
20808802
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,003
|
| 15899 |
Angiotensin (1-7)
|
|
decreases_activity of
|
NF-kappaB complex
|
in cardiac muscle
|
| 15917 |
Angiotensin (1-7)
|
|
decreases_activity of
|
I-kappaB kinase/NF-kappaB signaling
|
in cardiac muscle
|
| 15919 |
Angiotensin (1-7)
|
|
decreases_expression of
|
TLR2
|
in cardiac muscle
|
| 15920 |
Angiotensin (1-7)
|
|
decreases_expression of
|
IRAK1
|
in cardiac muscle
|
| 15921 |
Angiotensin (1-7)
|
|
decreases_expression of
|
IKBKB
|
in cardiac muscle
|
| 15923 |
Angiotensin (1-7)
|
|
decreases_expression of
|
C3
|
in cardiac muscle
|
| 15925 |
Angiotensin (1-7)
|
|
decreases_expression of
|
IL1B
|
in cardiac muscle
|
| 15926 |
Angiotensin (1-7)
|
|
decreases_expression of
|
IL6
|
in cardiac muscle
|
| 15928 |
Angiotensin (1-7)
|
|
decreases_expression of
|
NLRP12
|
in cardiac muscle
|
| 15929 |
Angiotensin (1-7)
|
|
decreases_expression of
|
CASP1
|
in cardiac muscle
|
| 15931 |
Angiotensin (1-7)
|
|
decreases_activity of
|
inflammatory response
|
in cardiac muscle
|
|
19166939
|
Diabetes mellitus, type II
Insulin resistance
|
|
9,686
|
| 102331 |
Angiotensin (1-7)
|
|
increases_quantity of
|
NO
|
in ventricular cardiomyocytes
|
| 102333 |
Angiotensin (1-7)
|
|
increases_phosphorylation of
|
AKT1
|
at Ser473
|
|
29443552
|
Cardiovascular disease
|
|
9,698
|
| 102346 |
Angiotensin (1-7)
|
|
increases_quantity of
|
Alamandine
|
|
|
23446738
|
Cardiovascular disease
|
|
11,717
|
| 116348 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116350 |
Angiotensin (1-7)
|
|
affects_activity of
|
insulin secretion
|
|
| 116374 |
Angiotensin (1-7)
|
|
affects_activity of
|
MAS1
|
|
| 116377 |
Angiotensin (1-7)
|
|
increases_quantity of
|
cAMP
|
in the cell
|
| 116434 |
Angiotensin (1-7)
|
|
decreases_activity of
|
response to oxidative stress
|
|
| 116435 |
MME
|
|
decreases_quantity of
|
Angiotensin (1-7)
|
|
|
30404071
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,748
|
| 116367 |
Angiotensin II
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via cleavage by ACE2 and other enzymes
|
| 116369 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116373 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
|
| 116375 |
Angiotensin (1-7)
|
|
increases_quantity of
|
Angiotensin (1-5)
|
|
| 116378 |
Angiotensin (1-7)
|
|
increases_activity of
|
AGTR2
|
but with lower affinity than ANG II
|
| 116398 |
PREP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
32333398
|
COVID-19
|
|
11,751
|
| 116894 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via catalytic action of MME (NEP)
|
| 116895 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via catalytic action of MME (NEP)
|
| 116896 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
15283675
|
Endocrine
|
|
11,756
|
| 116634 |
Angiotensin (1-7)
|
|
decreases_activity of
|
inflammatory response
|
in the alveolar microenvironment
|
|
32333398
|
COVID-19
|
|
11,758
|
| 116447 |
Angiotensin (1-7)
|
|
decreases_activity of
|
epithelial to mesenchymal transition
|
in A549 cells
|
| 116450 |
Angiotensin (1-7)
|
|
decreases_activity of
|
TGFB1
|
in A549 cells
|
| 116452 |
Angiotensin (1-7)
|
|
decreases_expression of
|
ZEB1
|
in A549 cells; via inhibition of TGFbeta1-SMAD signaling
|
| 116453 |
Angiotensin (1-7)
|
|
decreases_expression of
|
ZEB2
|
in A549 cells; via inhibition of TGFbeta1-SMAD signaling
|
| 116454 |
Angiotensin (1-7)
|
|
decreases_expression of
|
TWIST1
|
in A549 cells; via inhibition of TGFbeta1-SMAD signaling
|
| 116455 |
Angiotensin (1-7)
|
|
decreases_expression of
|
SNAI1
|
in A549 cells; via inhibition of TGFbeta1-SMAD signaling
|
| 116456 |
Angiotensin (1-7)
|
|
affects_activity of
|
MTOR
|
in A549 cells; via inhibition of TGFbeta1-SMAD signaling
|
|
31387171
|
Pulmonary fibrosis, idiopathic
|
|
11,776
|
| 116574 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-7)
|
|
| 116583 |
ACE
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116585 |
MME
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116587 |
PREP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116589 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116591 |
PRCP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116592 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
|
| 116598 |
Angiotensin (1-7)
|
|
increases_activity of
|
vasodilation
|
|
| 116600 |
Angiotensin (1-7)
|
|
decreases_activity of
|
thrombosis
|
|
| 116601 |
Angiotensin (1-7)
|
|
decreases_activity of
|
cell population proliferation
|
|
| 116602 |
Angiotensin (1-7)
|
|
increases_quantity of
|
NO
|
in vascular endothelial cells
|
| 116604 |
Angiotensin (1-7)
|
|
decreases_quantity of
|
Reactive oxygen species
|
in vascular endothelial cells
|
| 116605 |
Angiotensin (1-7)
|
|
increases_activity of
|
NOS3
|
in vascular endothelial cells
|
| 116606 |
Angiotensin (1-7)
|
|
decreases_activity of
|
atherosclerotic lesions
|
|
| 116610 |
Angiotensin (1-7)
|
|
decreases_activity of
|
Nephropathy, diabetic
|
|
| 116612 |
Angiotensin (1-7)
|
|
affects_activity of
|
renal sodium ion absorption
|
|
| 116614 |
Angiotensin (1-7)
|
|
affects_activity of
|
cardiac fibrosis
|
|
| 116624 |
Angiotensin (1-7)
|
|
decreases_activity of
|
abnormal circulating lipid level
|
|
| 116625 |
Angiotensin (1-7)
|
|
decreases_activity of
|
Insulin resistance
|
|
|
23463883
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
11,777
|
| 116632 |
embryo development
|
|
affects_quantity of
|
Angiotensin (1-7)
|
|
|
26029927
|
Diabetes mellitus, type II
Insulin resistance
|
|
11,821
|
| 116758 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116759 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
|
|
32341442
|
COVID-19
|
|
11,822
|
| 116790 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116795 |
Angiotensin II
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via the catalytic activity of ACE2
|
|
32336612
|
COVID-19
|
|
11,823
|
| 116809 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116810 |
Angiotensin II
|
|
increases_quantity of
|
Angiotensin (1-7)
|
via the action of ACE2
|
|
11815627
|
Metabolic
|
|
11,837
|
| 116874 |
ACE
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
| 116876 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-7)
|
|
| 116883 |
Angiotensin (1-7)
|
|
increases_quantity of
|
Angiotensin (1-5)
|
|
| 116884 |
Angiotensin (1-9)
|
|
increases_quantity of
|
Angiotensin (1-7)
|
|
|
10969042
|
Endocrine
|
|
11,842
|
| 116927 |
PRCP
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in kidney ; at acidic pH
|
| 116928 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in kidney ; at neutral to basic pH
|
|
23392115
|
Endocrine
|
|
11,844
|
| 116936 |
THOP1
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in hippocampus
|
| 116937 |
Angiotensin I
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in hippocampus; via the catalytic action of THOP1
|
|
24041943
|
Neurological
|
|
11,899
|
| 117136 |
ACE2, soluble
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in cerebrospinal fluid
|
|
28512108
|
Neurological
SARS-CoV infection
|
|
11,908
|
| 117213 |
Angiotensin (1-7)
|
|
increases_activity of
|
AGTR2
|
if candesartan is coadministered
|
| 117214 |
Angiotensin (1-7)
|
|
decreases_activity of
|
hypertension
|
if candesartan is coadministered
|
| 117217 |
Candesartan
|
|
affects_activity of
|
Angiotensin (1-7)
|
|
|
15767466
|
Cardiovascular disease
|
|
11,918
|
| 117246 |
Angiotensin (1-7)
|
|
increases_quantity of
|
Atrial natriuretic peptide
|
in atrium
|
|
27660028
|
Cardiovascular disease
|
|
11,922
|
| 117257 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
in LPS plus IFNG-stimulated macrophages
|
| 117270 |
Angiotensin (1-7)
|
|
decreases_expression of
|
TNF
|
in LPS plus IFNG-stimulated macrophages; via MAS1
|
| 117272 |
Angiotensin (1-7)
|
|
decreases_expression of
|
CCL2
|
in LPS plus IFNG-stimulated macrophages; via MAS1
|
| 117274 |
Angiotensin (1-7)
|
|
decreases_expression of
|
IL1B
|
in LPS plus IFNG-stimulated macrophages; via MAS1
|
| 117283 |
Angiotensin (1-7)
|
|
decreases_activity of
|
inflammatory response
|
in LPS plus IFNG-stimulated macrophages; via MAS1
|
|
30918468
|
Lung disease
|
|
11,928
|
| 117302 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
in HEK293 cells
|
| 117307 |
Angiotensin (1-7)
|
|
increases_activity of
|
MRGPRD
|
in HEK293 cells
|
| 117308 |
Angiotensin (1-7)
|
|
increases_activity of
|
Protein kinase A
|
in HUVECs
|
|
27217404
|
Cardiovascular disease
|
|
11,929
|
| 117303 |
Angiotensin (1-7)
|
|
increases_quantity of
|
cAMP
|
in the cell, in vascular smooth muscle cells, in mesangial cells
|
|
27217404
|
Cardiovascular disease
|
|
11,933
|
| 117315 |
Angiotensin (1-7)
|
|
interacts (colocalizes) with
|
AGTR2
|
in HEK293 cells
|
|
21542804
|
Cardiovascular disease
|
|
11,935
|
| 117317 |
Angiotensin (1-7)
|
NOT |
interacts (colocalizes) with
|
MAS1
|
|
| 117359 |
Angiotensin (1-7)
|
|
decreases_activity of
|
AGTR1
|
|
|
29928987
|
Cardiovascular disease
|
|
11,936
|
| 117318 |
Angiotensin (1-7)
|
|
increases_activity of
|
MAS1
|
in kidney
|
| 117360 |
Angiotensin (1-7)
|
|
increases_activity of
|
arachidonic acid secretion
|
|
|
12829792
|
Cardiovascular disease
|
|
11,937
|
| 117364 |
Angiotensin (1-7)
|
|
increases_expression of
|
CX3CR1
|
|
|
28461604
|
Cardiovascular disease
|
|
12,009
|
| 117645 |
FGF21
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in adipose tissue, in kidney; via ACE2
|
|
29706566
|
Cardiovascular disease
|
|
12,020
|
| 117800 |
ACE
|
|
decreases_quantity of
|
Angiotensin (1-7)
|
|
| 117804 |
Angiotensin (1-7)
|
|
increases_activity of
|
vasodilation
|
|
|
30934934
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
|
12,022
|
| 117883 |
ACE2
|
|
increases_quantity of
|
Angiotensin (1-7)
|
counterbalancing the effects of RAS via conversion of Ang II to Ang-(1-7)
|
|
30604460
|
Metabolic
Fatty liver disease, nonalcoholic
|
CIDeRplus